157 related articles for article (PubMed ID: 37694816)
1. Myopia outcome study of atropine in children: Two-year result of daily 0.01% atropine in a European population.
Loughman J; Kobia-Acquah E; Lingham G; Butler J; Loskutova E; Mackey DA; Lee SSY; Flitcroft DI
Acta Ophthalmol; 2024 May; 102(3):e245-e256. PubMed ID: 37694816
[TBL] [Abstract][Full Text] [Related]
2. Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control.
Yam JC; Jiang Y; Tang SM; Law AKP; Chan JJ; Wong E; Ko ST; Young AL; Tham CC; Chen LJ; Pang CP
Ophthalmology; 2019 Jan; 126(1):113-124. PubMed ID: 30514630
[TBL] [Abstract][Full Text] [Related]
3. Low-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control: A Randomized Clinical Trial.
Repka MX; Weise KK; Chandler DL; Wu R; Melia BM; Manny RE; Kehler LAF; Jordan CO; Raghuram A; Summers AI; Lee KA; Petersen DB; Erzurum SA; Pang Y; Lenhart PD; Ticho BH; Beck RW; Kraker RT; Holmes JM; Cotter SA;
JAMA Ophthalmol; 2023 Aug; 141(8):756-765. PubMed ID: 37440213
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Low-Dose Atropine Eyedrops for the Treatment of Myopia Progression in Chinese Children: A Randomized Clinical Trial.
Wei S; Li SM; An W; Du J; Liang X; Sun Y; Zhang D; Tian J; Wang N
JAMA Ophthalmol; 2020 Nov; 138(11):1178-1184. PubMed ID: 33001210
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of 0.01% and 0.1% low-dose atropine eye drop regimens for reduction of myopia progression in Danish children: a randomized clinical trial examining one-year effect and safety.
Hansen NC; Hvid-Hansen A; Møller F; Bek T; Larsen DA; Jacobsen N; Kessel L
BMC Ophthalmol; 2023 Oct; 23(1):438. PubMed ID: 37904082
[TBL] [Abstract][Full Text] [Related]
6. Myopia progression and axial elongation in Spanish children: Efficacy of atropine 0.01% eye-drops.
Moriche-Carretero M; Revilla-Amores R; Diaz-Valle D; Morales-Fernández L; Gomez-de-Liaño R
J Fr Ophtalmol; 2021 Dec; 44(10):1499-1504. PubMed ID: 34774348
[TBL] [Abstract][Full Text] [Related]
7. Myopia progression after cessation of low-dose atropine eyedrops treatment: A two-year randomized, double-masked, placebo-controlled, cross-over trial.
Wei S; Li SM; An W; Du J; Liang X; Sun Y; Gan J; Bai W; Tian J; Cai Z; Yin L; Wang N
Acta Ophthalmol; 2023 Mar; 101(2):e177-e184. PubMed ID: 35999653
[TBL] [Abstract][Full Text] [Related]
8. Age-related results over 2 years of the multicenter Spanish study of atropine 0.01% in childhood myopia progression.
Pérez-Flores I; Macías-Murelaga B; ; Barrio-Barrio J
Sci Rep; 2023 Sep; 13(1):16310. PubMed ID: 37770602
[TBL] [Abstract][Full Text] [Related]
9. Effect of Low-Concentration Atropine Eye Drops in Controlling the Progression of Myopia in Children: A One- and Two-Year Follow-Up Study.
Zhang H; Yang P; Li Y; Zhang W; Li S
Ophthalmic Epidemiol; 2024 Jun; 31(3):240-248. PubMed ID: 37528608
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study.
Hieda O; Hiraoka T; Fujikado T; Ishiko S; Hasebe S; Torii H; Takahashi H; Nakamura Y; Sotozono C; Oshika T; Morimoto T; Nishida K; Nishikawa N; Song YS; Tokutake T; Nishi Y; Shigeno Y; Kurihara T; Negishi K; Tsubota K; Ono M; Nakai T; Tan D; Tanaka S; Kinoshita S;
Jpn J Ophthalmol; 2021 May; 65(3):315-325. PubMed ID: 33586090
[TBL] [Abstract][Full Text] [Related]
11. Effect of Atropine 0.01% Eye Drops on the Difference in Refraction and Axial Length between Right and Left Eyes.
Liang X; Wei S; Li SM; An W; Du J; Sun Y; Gan J; Bai W; Cai Z; Song Q; Yin L; Wang N
Ophthalmic Res; 2023; 66(1):496-505. PubMed ID: 36603556
[TBL] [Abstract][Full Text] [Related]
12. Atropine for the treatment of childhood myopia.
Chua WH; Balakrishnan V; Chan YH; Tong L; Ling Y; Quah BL; Tan D
Ophthalmology; 2006 Dec; 113(12):2285-91. PubMed ID: 16996612
[TBL] [Abstract][Full Text] [Related]
13. Differential Effects on Ocular Biometrics by 0.05%, 0.025%, and 0.01% Atropine: Low-Concentration Atropine for Myopia Progression Study.
Li FF; Kam KW; Zhang Y; Tang SM; Young AL; Chen LJ; Tham CC; Pang CP; Yam JC
Ophthalmology; 2020 Dec; 127(12):1603-1611. PubMed ID: 32525048
[TBL] [Abstract][Full Text] [Related]
14. Effect of low-dose atropine on myopia progression, pupil diameter and accommodative amplitude: low-dose atropine and myopia progression.
Fu A; Stapleton F; Wei L; Wang W; Zhao B; Watt K; Ji N; Lyu Y
Br J Ophthalmol; 2020 Nov; 104(11):1535-1541. PubMed ID: 32086237
[TBL] [Abstract][Full Text] [Related]
15. Assessment of myopic rebound effect after discontinuation of treatment with 0.01% atropine eye drops in Japanese school-age children.
Hieda O; Hiraoka T; Fujikado T; Ishiko S; Hasebe S; Torii H; Takahashi H; Tanaka S; Kinoshita S;
Jpn J Ophthalmol; 2023 Sep; 67(5):602-611. PubMed ID: 37548816
[TBL] [Abstract][Full Text] [Related]
16. Two-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: Phase 2 Report.
Yam JC; Li FF; Zhang X; Tang SM; Yip BHK; Kam KW; Ko ST; Young AL; Tham CC; Chen LJ; Pang CP
Ophthalmology; 2020 Jul; 127(7):910-919. PubMed ID: 32019700
[TBL] [Abstract][Full Text] [Related]
17. Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine.
Tong L; Huang XL; Koh AL; Zhang X; Tan DT; Chua WH
Ophthalmology; 2009 Mar; 116(3):572-9. PubMed ID: 19167081
[TBL] [Abstract][Full Text] [Related]
18. Interventions to slow progression of myopia in children.
Walline JJ; Lindsley KB; Vedula SS; Cotter SA; Mutti DO; Ng SM; Twelker JD
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD004916. PubMed ID: 31930781
[TBL] [Abstract][Full Text] [Related]
19. Adjunctive effects of orthokeratology and atropine 0.01% eye drops on slowing the progression of myopia.
Zhou H; Zhao G; Li Y
Clin Exp Optom; 2022 Jul; 105(5):520-526. PubMed ID: 34228946
[TBL] [Abstract][Full Text] [Related]
20. Five-year results of atropine 0.01% efficacy in the myopia control in a European population.
Moriche-Carretero M; Revilla-Amores R; Gutiérrez-Blanco A; Moreno-Morillo FJ; Martinez-Perez C; Sánchez-Tena MÁ; Alvarez-Peregrina C
Br J Ophthalmol; 2024 May; 108(5):715-719. PubMed ID: 37268328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
